Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
The new Monash Antibody Technologies Facility (MATF) was officially opened at a ceremony attended by a number of dignitaries from the Australian government, academia and the life science industry. The newly refurbished, two hundred square meter facility houses cutting-edge equipment and boasts impressive capabilities for high throughput production of custom-made, high-affinity monoclonal antibodies.
Michael Spiegel, deputy director of MATF, said: “In just one year, and with Tecan’s support, we have renovated a whole new space, brought in state-of-the-art, fully automated systems and have them already producing antibodies. This is now the largest capacity and probably the most sophisticated and technologically advanced custom antibody facility in the world. We already have 50 academic projects in the pipeline and we are members of the structural genomic consortium, an international pilot project for creating binding agents to all human proteins and protein binders.“
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
